Insider · CIK 0002049427
Akos Czibere
Files at AKTS (Aktis Oncology, Inc.). First filing Jul 10, 2026, latest Sep 24, 2026.
In brief
Akos Czibere files SEC Form 4 as officer at AKTS (Aktis Oncology, Inc.). Since Jul 10, 2026, Akos Czibere has reported 0 open-market buys worth $0 and 2 open-market sells worth $1.6M, the latest filed on Sep 24, 2026.
A track record needs three past buys with six months of prices behind them; Akos Czibere has 0, so none is measured yet.
The newest scored trade: sold $259k of AKTS on Sep 23, 2026, filed Sep 24, 2026, scored 13 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $1.6M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKTS: Aktis Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Aktis Oncology, Inc. | $259k 12,500 shares | -100% | - | |
| 60Notable | Aktis Oncology, Inc. | $1.4M 50,000 shares | -100% | +89% from low-11% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 23, 2026 | AKTS AKTIS ONCOLOGY INC | 25,000 0.05% of outstanding | $553k | Sep 23, 2026 | $1.4M |
| Jul 8, 2026 | AKTS AKTIS ONCOLOGY, INC. | 50,000 0.09% of outstanding | $1.4M | Jul 8, 2026 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Common Stock10b5-1 | +12,500 | $4.95 | $62k | 12,500 | 20 d ago |
| Sep 23, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -5,099 | $20.19 | $103k | 7,401 | 20 d ago |
| Sep 23, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -7,401 | $21.03 | $156k | 0 | 20 d ago |
| Sep 23, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 208,718 | 20 d ago |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Common Stock | +50,000 | $4.95 | $248k | 50,000 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -14,800 | $27.13 | $401k | 35,200 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -30,829 | $27.95 | $862k | 4,371 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -4,371 | $28.71 | $125k | 0 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 221,218 | Jul 10, 2026 |
Questions about Akos Czibere
Answered from the filings on this page, as of the latest one.
Is Akos Czibere buying or selling?
In the last 12 months Akos Czibere reported 0 open-market buys worth $0 and 2 open-market sells worth $1.6M on SEC Form 4; the latest was sold $259k of AKTS on Sep 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Akos Czibere's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Akos Czibere has 0.
Where does Akos Czibere file Form 4?
Akos Czibere has filed Form 4 at AKTS (Aktis Oncology, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.